The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maker, A. V.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maker, A. V.
Right arrow Articles by Rosenberg, S. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Kidney Cancer
*Melanoma
The Journal of Immunology, 2005, 175: 7746-7754.
Copyright © 2005 by The American Association of Immunologists

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

Ajay V. Maker, Peter Attia and Steven A. Rosenberg1

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814

We have demonstrated previously that the administration of CTLA-4 blockade has mediated objective cancer regression and autoimmunity in patients with metastatic melanoma. To explore the mechanism of these in vivo effects, we have studied the changes in lymphocyte phenotype and function in patients receiving anti-CTLA-4 Ab (MDX-010). Patients with stage IV melanoma or renal cell cancer were treated every 3 wk with an anti-CTLA-4 Ab with or without peptide immunization. Pheresis samples were analyzed using flow cytometry to determine lymphocyte cell surface markers. Gene expression analyses and proliferation assays were conducted on purified T cell subsets. Anti-CTLA-4 Ab did not inhibit the suppressive activity of CD4+CD25+ cells in vitro or in vivo. In addition, there was no decrease in the expression of CD4+CD25+ cells in whole PBMC, nor a decrease in Foxp3 gene expression in the CD4+ or CD4+CD25+ purified cell populations posttreatment. The percentage of CD4+, CD8+, CD4+CD25+, and CD4+CD25– T cells in PBMC expressing the activation marker HLA-DR increased following anti-CTLA-4 Ab administration. Therefore, our results suggest that the antitumor effects of CTLA-4 blockade are due to increased T cell activation rather than inhibition or depletion of T regulatory cells.




This article has been cited by other articles:


Home page
 NDT PlusHome page
E. C. Jolly, M. R. Clatworthy, C. Lawrence, P. D. Nathan, and K. Farrington
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
NDT Plus, August 1, 2009; 2(4): 300 - 302.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. B. Jacob, Y.-c. M. Kong, I. Nalbantoglu, D. P. Snower, and W.-Z. Wei
Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for Autoimmunity
J. Immunol., May 1, 2009; 182(9): 5873 - 5881.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Fong, S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, et al.
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Cancer Res., January 15, 2009; 69(2): 609 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ribas, B. Comin-Anduix, J. S. Economou, T. R. Donahue, P. de la Rocha, L. F. Morris, J. Jalil, V. B. Dissette, I. P. Shintaku, J. A. Glaspy, et al.
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Clin. Cancer Res., January 1, 2009; 15(1): 390 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Yuan, S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, N. H. Segal, T. S. Rasalan, et al.
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
PNAS, December 23, 2008; 105(51): 20410 - 20415.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Fong and E. J. Small
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
J. Clin. Oncol., November 10, 2008; 26(32): 5275 - 5283.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. D. Wolchok and Y. Saenger
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Oncologist, October 1, 2008; 13(suppl_4): 2 - 9.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. I. Liakou, A. Kamat, D. N. Tang, H. Chen, J. Sun, P. Troncoso, C. Logothetis, and P. Sharma
CTLA-4 blockade increases IFN{gamma}-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
PNAS, September 30, 2008; 105(39): 14987 - 14992.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Menard, F. Ghiringhelli, S. Roux, N. Chaput, C. Mateus, U. Grohmann, S. Caillat-Zucman, L. Zitvogel, and C. Robert
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Clin. Cancer Res., August 15, 2008; 14(16): 5242 - 5249.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Blood, August 15, 2008; 112(4): 1175 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. L. Alderson, Q. Zhou, V. Berner, D. E. C. Wilkins, J. M. Weiss, B. R. Blazar, L. A. Welniak, R. H. Wiltrout, D. Redelman, and W. J. Murphy
Regulatory and Conventional CD4+ T Cells Show Differential Effects Correlating with PD-1 and B7-H1 Expression after Immunotherapy
J. Immunol., March 1, 2008; 180(5): 2981 - 2988.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, T. E. Allen, C. L. Levy, et al.
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Clin. Cancer Res., November 15, 2007; 13(22): 6681 - 6688.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al.
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo
J. Immunol., October 1, 2007; 179(7): 4919 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. S. Hodi
Cytotoxic T-Lymphocyte Associated Antigen-4
Clin. Cancer Res., September 15, 2007; 13(18): 5238 - 5242.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zang and J. P. Allison
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clin. Cancer Res., September 15, 2007; 13(18): 5271 - 5279.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. B. Jacob, Y.-c. M. Kong, C. Meroueh, D. P. Snower, C. S. David, Y.-S. Ho, and W.-Z. Wei
Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells
Cancer Res., July 15, 2007; 67(14): 7020 - 7027.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. S. Mohamood, M. L. Guler, Z. Xiao, D. Zheng, A. Hess, Y. Wang, H. Yagita, J. P. Schneck, and A. R. A. Hamad
Protection from Autoimmune Diabetes and T-Cell Lymphoproliferation Induced by FasL Mutation Are Differentially Regulated and Can Be Uncoupled Pharmacologically
Am. J. Pathol., July 1, 2007; 171(1): 97 - 106.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Weber
Review: Anti CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Oncologist, July 1, 2007; 12(7): 864 - 872.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Ribas, D. C. Hanson, D. A. Noe, R. Millham, D. J. Guyot, S. H. Bernstein, P. C. Canniff, A. Sharma, and J. Gomez-Navarro
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
Oncologist, July 1, 2007; 12(7): 873 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Tuve, B.-M. Chen, Y. Liu, T.-L. Cheng, P. Toure, P. S. Sow, Q. Feng, N. Kiviat, R. Strauss, S. Ni, et al.
Combination of Tumor Site-Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Cancer Res., June 15, 2007; 67(12): 5929 - 5939.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. M. Gabriel and E. C. Lattime
Anti-CTL-Associated Antigen 4: Are Regulatory T Cells a Target?
Clin. Cancer Res., February 1, 2007; 13(3): 785 - 788.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev
Reversal of Tumor-Mediated Immunosuppression
Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Ferretti, A. Felici, M. S. Pino, and F. Cognetti
Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells?
J. Clin. Oncol., December 1, 2006; 24(34): 5469 - 5470.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Read, R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A. H. Sharpe, and F. Powrie
Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo
J. Immunol., October 1, 2006; 177(7): 4376 - 4383.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. E. Beck, J. A. Blansfield, K. Q. Tran, A. L. Feldman, M. S. Hughes, R. E. Royal, U. S. Kammula, S. L. Topalian, R. M. Sherry, D. Kleiner, et al.
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4
J. Clin. Oncol., May 20, 2006; 24(15): 2283 - 2289.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. O'Mahony and J. E. Janik
Comment on "Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade"
J. Immunol., May 1, 2006; 176(9): 5136 - 5136.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
J. J. A. Coenen, H. J. P. M. Koenen, E. van Rijssen, L. Boon, I. Joosten, and L. B. Hilbrands
CTLA-4 Engagement and Regulatory CD4+CD25+ T Cells Independently Control CD8+-Mediated Responses under Costimulation Blockade
J. Immunol., May 1, 2006; 176(9): 5240 - 5246.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Rosenberg
Response to Comment on "Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade"
J. Immunol., May 1, 2006; 176(9): 5136 - 5136.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Danson and P. Lorigan
Melanoma vaccines - they should work
Ann. Onc., April 1, 2006; 17(4): 539 - 541.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.